BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON: Form 990, tax year 2019
View the entire original 990 at ProPublica ↗
- Organization
- BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (EIN 91-0653422)
- Tax period
- 2019-01-01 to 2019-12-31
- Filed
- 2020-11-11
- IRS object ID
- 202013169349303241
- Schema version
- 2019v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule K
- Schedule O
- Schedule R
- Affiliated Group Schedule
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2020-11-11T11:44:59-00:00 | ReturnTs |
| Tax Period End | 2019-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KPMG LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1918 8th Avenue Suite 2900 | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98101 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2019-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 910653422 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Benaroya Research Institute at Virginia Mason | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | BENA | BusinessNameControlTxt |
| Phone | 2063426500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1201 Ninth Avenue | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98101 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Michael Labosier | PersonNm |
| Person Title | Chief Financial Officer | PersonTitleTxt |
| Signature | 2020-11-11 | SignatureDt |
| Discuss With Paid Preparer | Yes (true) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | Sue Robison | PreparerPersonNm |
| Phone | 2069134000 | PhoneNum |
| Preparation | 2020-11-11 | PreparationDt |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 204.147.223.1 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2020-11-11 | IPDt |
| IP Tm | 19:42:56 | IPTm |
| IP Timezone | PS | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | 2D777907B0975C575C8D1E5F6EEE6AF7977F0150 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | D8897A10968BD4A76AAFC1D10C660AAB2141E34A | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2019 | TaxYr |
| Build TS | 2021-01-29 14:40:06Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | Jane Buckner MD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1201 Ninth Avenue | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 981012795 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $73,469,519 | GrossReceiptsAmt |
| Group Return For Affiliates | false | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | benaroyaresearch.org | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1956 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | To advance the science that will predict, prevent, reverse, and cure diseases of the immune system. | ActivityOrMissionDesc |
| Voting Members Governing Body | 21 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 16 | VotingMembersIndependentCnt |
| Total Employee | 336 | TotalEmployeeCnt |
| Total Volunteers | 7 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| PY Contributions Grants | $59,023,034 | PYContributionsGrantsAmt |
| CY Contributions Grants | $62,867,601 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $8,229,643 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $9,656,398 | CYProgramServiceRevenueAmt |
| PY Investment Income | $191,489 | PYInvestmentIncomeAmt |
| CY Investment Income | $322,628 | CYInvestmentIncomeAmt |
| PY Other Revenue | $347,680 | PYOtherRevenueAmt |
| CY Other Revenue | $432,312 | CYOtherRevenueAmt |
| PY Total Revenue | $67,791,846 | PYTotalRevenueAmt |
| CY Total Revenue | $73,278,939 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $22,634,522 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $23,652,782 | CYGrantsAndSimilarPaidAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $26,095,485 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $29,080,641 | CYSalariesCompEmpBnftPaidAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $18,050,564 | PYOtherExpensesAmt |
| CY Other Expenses | $18,713,253 | CYOtherExpensesAmt |
| PY Total Expenses | $66,780,571 | PYTotalExpensesAmt |
| CY Total Expenses | $71,446,676 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $1,011,275 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $1,832,263 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $84,112,856 | TotalAssetsBOYAmt |
| Total Assets EOY | $95,747,100 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $39,800,841 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $45,073,162 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $44,312,015 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $50,673,938 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | Advancing the science that will predict, prevent, reverse, and cure diseases of the immune system such as autoimmune disease, allergy, and asthma. | MissionDesc |
| Significant New Program Srvc | false | SignificantNewProgramSrvcInd |
| Significant Change | false | SignificantChangeInd |
| Expense | $27,576,900 | ExpenseAmt |
| Grant | $21,982,621 | GrantAmt |
| Desc | Immune Tolerance Network Program. See Schedule O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $8,899,817 | ExpenseAmt |
| Grant | $1,279,738 | GrantAmt |
| Desc | Fundamental Immunology Programs - Includes Fundamental Immunology. See Schedule O. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $9,436,609 | ExpenseAmt |
| Grant | $158,099 | GrantAmt |
| Desc | Translational, Clinical, and Systems Programs - Includes Translational, Systems, Interventional, and CRP. See Schedule O. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $13,057,014 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $232,324 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $9,656,398 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $58,970,340 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (true) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (true) | ScheduleBRequiredInd |
| Political Campaign Acty | false | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (true) | LobbyingActivitiesInd |
| Subject To Proxy Tax | false | SubjectToProxyTaxInd |
| Donor Advised Fund | false | DonorAdvisedFundInd |
| Conservation Easements | false | ConservationEasementsInd |
| Collections Of Art | false | CollectionsOfArtInd |
| Credit Counseling | false | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (true) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (true) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | Yes (true) | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | false | ReportProgramRelatedInvstInd |
| Report Other Assets | false | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (true) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | false | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (true) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | false | ConsolidatedAuditFinclStmtInd |
| School Operating | false | SchoolOperatingInd |
| Foreign Office | false | ForeignOfficeInd |
| Foreign Activities | Yes (true) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (true) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | false | MoreThan5000KToIndividualsInd |
| Professional Fundraising | false | ProfessionalFundraisingInd |
| Fundraising Activities | false | FundraisingActivitiesInd |
| Gaming Activities | false | GamingActivitiesInd |
| Operate Hospital | false | OperateHospitalInd |
| Grants To Organizations | Yes (true) | GrantsToOrganizationsInd |
| Grants To Individuals | false | GrantsToIndividualsInd |
| Schedule J Required | Yes (true) | ScheduleJRequiredInd |
| Tax Exempt Bonds | Yes (true) | TaxExemptBondsInd |
| Invest Tax Exempt Bonds | false | InvestTaxExemptBondsInd |
| Escrow Account | false | EscrowAccountInd |
| On Behalf Of Issuer | Yes (true) | OnBehalfOfIssuerInd |
| Engaged In Excess Benefit Trans | false | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | false | PYExcessBenefitTransInd |
| Loan Outstanding | false | LoanOutstandingInd |
| Grant To Related Person | false | GrantToRelatedPersonInd |
| Business Rln With Org Mem | false | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | false | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | false | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | false | DeductibleNonCashContriInd |
| Deductible Art Contribution | false | DeductibleArtContributionInd |
| Terminate Operations | false | TerminateOperationsInd |
| Partial Liquidation | false | PartialLiquidationInd |
| Disregarded Entity | false | DisregardedEntityInd |
| Related Entity | Yes (true) | RelatedEntityInd |
| Related Organization Ctrl Ent | false | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | false | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | false | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | false | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (true) | ScheduleORequiredInd |
| IRP Document | 82 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (true) | BackupWthldComplianceInd |
| Employee | 336 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (true) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | false | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | false | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | false | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | false | TaxablePartyNotificationInd |
| Nondeductible Contributions | false | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | false | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | false | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | false | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | false | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | false | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | false | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | false | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 21 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 16 | IndependentVotingMemberCnt |
| Family Or Business Rln | false | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | false | DelegationOfMgmtDutiesInd |
| Change To Org Documents | false | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | false | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (true) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (true) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (true) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (true) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (true) | MinutesOfCommitteesInd |
| Officer Mailing Address | false | OfficerMailingAddressInd |
| Local Chapters | false | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (true) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (true) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (true) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (true) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (true) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (true) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (true) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (true) | CompensationProcessOtherInd |
| Investment In Joint Venture | false | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | Michael Labosier CFO | PersonNm |
| Phone | 2063426505 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1201 Ninth Avenue | AddressLine1Txt |
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98101 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (30 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Key EmployeeKeyEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| Gary Kaplan MD | |||||||||
| Director | 001.00 | 054.00 | Yes (X) | $0 | $1,661,792 | $331,024 | |||
| David Aboulafia MD | |||||||||
| Director | 001.00 | 050.00 | Yes (X) | $0 | $635,488 | $59,144 | |||
| Joyce Lammert MD PhD | |||||||||
| Director | 001.00 | 050.00 | Yes (X) | $0 | $534,963 | $104,561 | |||
| Jane Buckner MD | |||||||||
| Ex Officio, President | 040.00 | Yes (X) | $492,418 | $0 | $26,200 | Yes (X) | |||
| William Kowk PhD | |||||||||
| Research Member | 040.00 | $244,059 | $0 | $28,600 | Yes (X) | ||||
| Carla Greenbaum MD | |||||||||
| Director | 040.00 | Yes (X) | $238,252 | $0 | $31,562 | ||||
| Steven Ziegler PhD | |||||||||
| Director of Academic Affairs | 040.00 | $234,294 | $0 | $22,978 | Yes (X) | ||||
| Margaret McCormick PhD | |||||||||
| Executive Director Chief Operating Officer | 040.00 | $218,634 | $0 | $30,800 | Yes (X) | ||||
| Michael Labosier | |||||||||
| Chief Financial Officer | 040.00 | $191,450 | $0 | $25,562 | Yes (X) | ||||
| Bolong Cao | |||||||||
| Business Development Director, Business Development | 040.00 | $186,128 | $0 | $29,474 | Yes (X) | ||||
| Lynn Rose | |||||||||
| Director of Scientific Administration | 040.00 | $190,130 | $0 | $22,010 | Yes (X) | ||||
| Daniel Campbell PhD | |||||||||
| Center Director of Discovery Science | 040.00 | $186,514 | $0 | $17,729 | Yes (X) | ||||
| Gerald Nepom MD PhD | |||||||||
| Program Director, ITN | 024.00 | $158,330 | $0 | $27,444 | Yes (X) | ||||
| Homer Lane | |||||||||
| Executive Director Chief Financial Officer | 040.00 | $168,551 | $0 | $6,985 | Yes (X) | ||||
| Catherine Zimmerman | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Jeffrey S Wortley | |||||||||
| Director, Treasurer | 001.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| Christopher Wilson MD | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| David Williams | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Diane St John | |||||||||
| Director, Secretary | 001.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| Proctor Shenk | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Nabil Istafanous | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Paul Hughes | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Michael Gallatin | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Frank Dvorak PhD | |||||||||
| Director, Vice-Chair | 001.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| Carla DewBerry | |||||||||
| Director, Chair | 001.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | |||
| Tom Cohen | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Rebecca Campbell | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Ben Reiber | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Kirk Nelson | |||||||||
| Director | 001.00 | Yes (X) | $0 | $0 | $0 | ||||
| Robert Williams | |||||||||
| Director | 001.00 | 002.00 | Yes (X) | $0 | $0 | $0 | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,508,760 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $2,832,243 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $764,073 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 53 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | false | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (true) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | false | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (4 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| DNA Brand Mechanics | |||||
| 1301 Fifth Avenue Suite 2600 | Seattle | WA | 98101 | Professional Services | $146,247 |
| KPMG LLP | |||||
| 1918 Eighth Avenue Suite 2900 | Seattle | WA | 98101 | Auditing Consulting | $115,616 |
| Riverbend Design Group LLC | |||||
| 414 Stewart St suite 215 | Seattle | WA | 98101 | Web Development Digital Communications | $110,310 |
| Finley & Cook | |||||
| 601 N Broadway | Shawnee | OK | 74802 | Software Support | $106,353 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 4 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $3,000,000 | RelatedOrganizationsAmt |
| Government Grants | $48,266,738 | GovernmentGrantsAmt |
| All Other Contributions | $11,600,863 | AllOtherContributionsAmt |
| Total Contributions | $62,867,601 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| Commercial Studies | 621500 | $4,280,875 | $4,280,875 |
| Collaborative Research Core Services | 621500 | $5,375,523 | $5,375,523 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $9,656,398 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $322,628 | TotalRevenueColumnAmt |
| Exclusion | $322,628 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $622,892 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $190,580 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $432,312 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $432,312 | TotalRevenueColumnAmt |
| Exclusion | $432,312 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $73,278,939 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $9,656,398 | RelatedOrExemptFuncIncomeAmt |
| Exclusion | $754,940 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $21,460,813 | TotalAmt |
| Program Services | $21,460,813 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,191,969 | TotalAmt |
| Program Services | $2,191,969 | ProgramServicesAmt |
Benefits To Members BenefitsToMembersGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,443,449 | TotalAmt |
| Program Services | $663,622 | ProgramServicesAmt |
| Management And General | $779,827 | ManagementAndGeneralAmt |
Comp Disqual Persons CompDisqualPersonsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $20,938,237 | TotalAmt |
| Program Services | $15,192,282 | ProgramServicesAmt |
| Management And General | $5,745,955 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,769,420 | TotalAmt |
| Program Services | $1,231,506 | ProgramServicesAmt |
| Management And General | $537,914 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,230,520 | TotalAmt |
| Program Services | $2,248,421 | ProgramServicesAmt |
| Management And General | $982,099 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,699,015 | TotalAmt |
| Program Services | $1,182,504 | ProgramServicesAmt |
| Management And General | $516,511 | ManagementAndGeneralAmt |
Fees For Services Management FeesForServicesManagementGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,413 | TotalAmt |
| Management And General | $9,413 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $115,616 | TotalAmt |
| Management And General | $115,616 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fees For Services Prof Fundraising | FeesForServicesProfFundraising |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,343,708 | TotalAmt |
| Program Services | $1,641,280 | ProgramServicesAmt |
| Management And General | $702,428 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $177,242 | TotalAmt |
| Program Services | $745 | ProgramServicesAmt |
| Management And General | $176,497 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $122,182 | TotalAmt |
| Program Services | $23,165 | ProgramServicesAmt |
| Management And General | $99,017 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,403,630 | TotalAmt |
| Program Services | $653,435 | ProgramServicesAmt |
| Management And General | $750,195 | ManagementAndGeneralAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,401,852 | TotalAmt |
| Program Services | $2,805,144 | ProgramServicesAmt |
| Management And General | $596,708 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $347,489 | TotalAmt |
| Program Services | $268,212 | ProgramServicesAmt |
| Management And General | $79,277 | ManagementAndGeneralAmt |
Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $114,501 | TotalAmt |
| Program Services | $84,941 | ProgramServicesAmt |
| Management And General | $29,560 | ManagementAndGeneralAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $758,201 | TotalAmt |
| Program Services | $659,635 | ProgramServicesAmt |
| Management And General | $98,566 | ManagementAndGeneralAmt |
Payments To Affiliates PaymentsToAffiliatesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $0 | TotalAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,254,492 | TotalAmt |
| Program Services | $2,602,540 | ProgramServicesAmt |
| Management And General | $651,952 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $57,358 | TotalAmt |
| Management And General | $57,358 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| Supplies and Miscellaneous Expenses | $4,446,355 | $4,322,029 | $124,326 |
| Other Purchased Services | $380,574 | $243,263 | $137,311 |
| Patient Costs | $976,976 | $976,976 | |
| Research Participants Expenses | $341,518 | $341,448 | $70 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $462,146 | TotalAmt |
| Program Services | $176,410 | ProgramServicesAmt |
| Management And General | $285,736 | ManagementAndGeneralAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $71,446,676 | TotalAmt |
| Program Services | $58,970,340 | ProgramServicesAmt |
| Management And General | $12,476,336 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,711,406 | BOYAmt |
| EOY | $5,968,573 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $576,745 | BOYAmt |
| EOY | $1,346,562 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $11,995,906 | BOYAmt |
| EOY | $13,407,687 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,591,784 | BOYAmt |
| EOY | $2,190,375 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $509,432 | BOYAmt |
| EOY | $642,728 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $75,226,693 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $51,536,267 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $24,914,121 | BOYAmt |
| EOY | $23,690,426 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $12,066,383 | BOYAmt |
| EOY | $12,334,516 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $25,745,020 | BOYAmt |
| EOY | $33,053,950 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,002,059 | BOYAmt |
| EOY | $3,112,283 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $84,112,856 | BOYAmt |
| EOY | $95,747,100 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,535,580 | BOYAmt |
| EOY | $10,369,555 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,548,771 | BOYAmt |
| EOY | $6,925,668 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $25,716,490 | BOYAmt |
| EOY | $25,037,716 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | $2,740,223 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $39,800,841 | BOYAmt |
| EOY | $45,073,162 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $17,232,381 | BOYAmt |
| EOY | $17,545,065 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $27,079,634 | BOYAmt |
| EOY | $33,128,873 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $44,312,015 | BOYAmt |
| EOY | $50,673,938 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $84,112,856 | BOYAmt |
| EOY | $95,747,100 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $1,832,263 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $4,529,660 | NetUnrlzdGainsLossesInvstAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | false | AccountantCompileOrReviewInd |
| FS Audited | Yes (true) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (true) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (true) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (true) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Medical Research Organization | Yes (X) | MedicalResearchOrganizationInd |
Hospital Name And Address HospitalNameAndAddressGrp
Supported Organization Name SupportedOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | Virginia Mason Medical Center | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| City | Seattle | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $59,709,893 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $71,346,495 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $60,243,416 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $59,023,034 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $62,867,601 | CurrentTaxYearAmt |
| Total | $313,190,439 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $59,709,893 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $71,346,495 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $60,243,416 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $59,023,034 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $62,867,601 | CurrentTaxYearAmt |
| Total | $313,190,439 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $30,081,850 | SubstantialContributorsTotAmt |
| Public Support Total170 | $283,108,589 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $430,555 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $933,027 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $994,910 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $729,749 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $945,520 | CurrentTaxYearAmt |
| Total | $4,033,761 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,021,290 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $8,553,010 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $6,781,431 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $8,229,643 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $9,656,398 | CurrentTaxYearAmt |
| Total | $40,241,772 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $357,465,972 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $40,241,772 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.79200 | PublicSupportCY170Pct |
| Public Support PY170 | 0.79680 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
| Public Support CY509 | 0.00000 | PublicSupportCY509Pct |
| Investment Income CY | 0.00000 | InvestmentIncomeCYPct |
| Facts And Circumstances Test | Part II Section B Line 10 2019 Other Income of 9,656,398 is comprised of 4,280,875 of Clinical Research Program revenue, 4,453,944 of Collaborative Research Agreement projects, 886,743 of External Core Income, and 34,836 of miscellaneous income. | FactsAndCircumstancesTestTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Belongs Afflt Grp | Yes (X) | OrganizationBelongsAffltGrpInd |
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Affiliated Group Total | $183,519 | AffiliatedGroupTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Affiliated Group Total | $123,581 | AffiliatedGroupTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Affiliated Group Total | $307,100 | AffiliatedGroupTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $71,446,676 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $1,766,048,047 | AffiliatedGroupTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $71,446,676 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $1,766,355,147 | AffiliatedGroupTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $1,000,000 | AffiliatedGroupTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
| Affiliated Group Total | $250,000 | AffiliatedGroupTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $275,782 | CurrentYearMinus3Amt |
| Current Year Minus2 | $284,247 | CurrentYearMinus2Amt |
| Current Year Minus1 | $294,038 | CurrentYearMinus1Amt |
| Current Year | $307,100 | CurrentYearAmt |
| Total | $1,161,167 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $163,134 | CurrentYearMinus3Amt |
| Current Year Minus2 | $175,480 | CurrentYearMinus2Amt |
| Current Year Minus1 | $180,464 | CurrentYearMinus1Amt |
| Current Year | $183,519 | CurrentYearAmt |
| Total | $702,597 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | false | VolunteersInd |
| Paid Staff Or Management | false | PaidStaffOrManagementInd |
| Media Advertisements | false | MediaAdvertisementsInd |
| Mailings Members | false | MailingsMembersInd |
| Publications Or Broadcast | false | PublicationsOrBroadcastInd |
| Grants Other Organizations | false | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | false | DirectContactLegislatorsInd |
| Rallies Demonstrations | false | RalliesDemonstrationsInd |
| Other Activities | false | OtherActivitiesInd |
| Not Described Section501c3 | false | NotDescribedSection501c3Ind |
| Form4720 Filed4912 Tax | false | Form4720Filed4912TaxInd |
Supplemental Information Detail SupplementalInformationDetail (5 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| II-A A | Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0.Benaroya Research Institute at Virginia Mason, EIN 91-0653422, 1201 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0. |
| II-A A continued | Virginia Mason Medical Center, EIN 91-0565539, 1100 Ninth Avenue, Seattle, WA 98101. Electing member. Grassroots Lobbying Expenditures 134,909 Direct Lobbying Expenditures 63,581. Excess Lobbying Expenditures 0. Tax year ending December 31, 1998 was the first year in which Virginia Mason Medical Center made the election under Section 501h. The election was not revoked before the start of the tax year ending December 31, 2019. |
| II-A A continued | Virginia Mason Health System, EIN 91-1351110, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures. Excess Lobbying Expenditures 0 |
| II-A A continued | Virginia Mason Institute, EIN 26-3763656, 1100 Ninth Avenue, Seattle, WA 98101. Non-electing member. 0 Lobbying Expenditures, 0 Excess Lobbying Expenditures. |
| II-A A continued | Yakima Valley Memorial Hospital Association, EIN 91-0567263, 2811 Tieton Drive, Yakima, WA 98902. Non-electing member. 48,610 Grassroots Lobbying Expenditures 60,000 Direct Lobbying Expenditures. Excess Lobbying Expenditures 0. |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Incl Escrow Custodial Acct Liab | false | InclEscrowCustodialAcctLiabInd |
| Endowments Held Unrelated Org | false | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | Yes (true) | EndowmentsHeldRelatedOrgInd |
| Related Org List Sch R | Yes (true) | RelatedOrgListSchRInd |
Land LandGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $756,906 | OtherCostOrOtherBasisAmt |
| Book Value | $756,906 | BookValueAmt |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $49,852,993 | OtherCostOrOtherBasisAmt |
| Depreciation | $30,754,795 | DepreciationAmt |
| Book Value | $19,098,198 | BookValueAmt |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $215,595 | OtherCostOrOtherBasisAmt |
| Depreciation | $199,672 | DepreciationAmt |
| Book Value | $15,923 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $23,141,650 | OtherCostOrOtherBasisAmt |
| Depreciation | $20,581,800 | DepreciationAmt |
| Book Value | $2,559,850 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $1,259,549 | OtherCostOrOtherBasisAmt |
| Book Value | $1,259,549 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $23,690,426 | TotalBookValueLandBuildingsAmt |
Other Securities OtherSecuritiesGrp (3 entries)
| DescDesc | Book ValueBookValueAmt | Method ValuationMethodValuationCd |
|---|---|---|
| Financial derivatives and other financial products | ||
| Closely-held equity interests | ||
| Interest in Net Assets of Virginia Mason Health System | $33,053,950 | F |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Securities | $33,053,950 | TotalBookValueSecuritiesAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| Federal income taxes | |
| Lease liability Relates to Right-of-Use Asset | $2,740,223 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $2,740,223 | TotalLiabilityAmt |
| Total Rev Etc Audited Fincl Stmt | $77,808,599 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $4,529,660 | NetUnrealizedGainsInvstAmt |
| Revenue Not Reported | $4,529,660 | RevenueNotReportedAmt |
| Revenue Subtotal | $73,278,939 | RevenueSubtotalAmt |
| Total Revenue Per Form990 | $73,278,939 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $71,446,676 | TotExpnsEtcAuditedFinclStmtAmt |
| Expenses Subtotal | $71,446,676 | ExpensesSubtotalAmt |
| Total Expenses Per Form990 | $71,446,676 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | X 1, Row 2 | FormAndLineReferenceDesc |
| Explanation | In accordance with ASC topic 842 Leases, the Research Institute adopted the new standard and recorded lease liabilities over lease terms between 3 and 10 years. The leases are primarily for real estate, including off-campus outpatient facilities, medical office buildings, and corporate and administrative offices. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)
| RegionRegionTxt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|
| Europe Including Iceland and Greenland | Conferences | Medical Research | $29,451 |
| East Asia and the Pacific | Conferences | Medical Research | $4,213 |
| North America | Conferences | Medical Research | $1,283 |
| Europe Including Iceland and Greenland | Grant | Medical Research | $1,789,606 |
| East Asia and the Pacific | Grant | Medical Research | $394,025 |
| North America | Grant | Medical Research | $8,337 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Spent | $2,226,915 | SubtotalSpentAmt |
| Total Spent | $2,226,915 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (10 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| Europe Including Iceland and Greenland | Medical Research | $811,655 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $596,423 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $231,032 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $134,225 | Wire Transfer |
| Europe Including Iceland and Greenland | Medical Research | $16,271 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $277,258 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $96,526 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $12,494 | Wire Transfer |
| East Asia and the Pacific | Medical Research | $7,747 | Wire Transfer |
| North America | Medical Research | $8,337 | Wire Transfer |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 10 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | false | TransferToForeignCorpInd |
| Interest In Foreign Trust | false | InterestInForeignTrustInd |
| Foreign Corp Ownership | false | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | false | PassiveForeignInvestmestCoInd |
| Foreign Partnership | false | ForeignPartnershipInd |
| Boycott Countries | false | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Line 2 | Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. |
| Part I Line 3f | The expenditures were actual expenses incurred in the region based on individual expense reports and tracking of expenditures by grant or department on the accrual basis of accounting. |
| Part II Line 1 | The expenditures were expenses incurred in the region based on award goals on the accrual basis of accounting. |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (true) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (57 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| Ann&Robert H Lurie Children's Hospital of Chicago | |||||||
| 225 East Chicago Ave No 205 | Chicago | IL | 606112991 | 362170833 | 501c3 | $11,685 | Medical Research |
| Arkansas Children's Hospital Research Institute | |||||||
| One Childrens Way | Little Rock | AR | 722023591 | 710694931 | 501c3 | $46,507 | Medical Research |
| Asthma Inc | |||||||
| 9725 3rd Ave NE | Seattle | WA | 98115 | 237219813 | 501c3 | $18,988 | Medical Research |
| Children's Hosp of Philadelphia | |||||||
| PO Box 8550 | Phliladelphia | PA | 191781457 | 231352166 | 501c3 | $67,524 | Medical Research |
| Children's Mercy Hospital | |||||||
| 2401 Gillham Road | Kansas City | MO | 64101 | 440605373 | 501c3 | $41,893 | Medical Research |
| The Cleveland Clinic Foundation | |||||||
| 9500 Euclid Avenue JJN5-001 | Cleveland | OH | 44195 | 340714585 | 501c3 | $97,334 | Medical Research |
| Columbia University Trustees of | |||||||
| PO Box 29789 | New York | NY | 100879789 | 135598093 | 501c3 | $80,903 | Medical Research |
| Dana-Farber Cancer Institute Inc | |||||||
| Attn Research Accounting | Boston | MA | 02215 | 042263040 | 501c3 | $115,073 | Medical Research |
| Denver Nephrologists PC | |||||||
| 130 Rampart Way Suite 300B | Denver | CO | 80230 | 840591433 | $13,538 | Medical Research | |
| Duke University | |||||||
| PO Box 602651 | Charlotte | NC | 282602651 | 560532129 | 501c3 | $1,287,080 | Medical Research |
| Emory University | |||||||
| PO Box 935084 | Atlanta | GA | 311935084 | 580566256 | 501c3 | $201,493 | Medical Research |
| Feinstein Institute for Medical Research | |||||||
| 350 Community Drive | Manhasset | NY | 11030 | 112673595 | 501c3 | $167,098 | Medical Research |
| Fred Hutchinson Cancer Research Center | |||||||
| Mailstop J6-330 | Seattle | WA | 98109 | 237156071 | 501c3 | $257,933 | Medical Research |
| Hospital for Special Surgery | |||||||
| 535 East 70th Str | New York | NY | 10021 | 131624135 | 501c3 | $12,868 | Medical Research |
| Icahn School of Medicine at Mount Sinai | |||||||
| One Gustave L Levy Place Box 3500 | New York | NY | 100296574 | 136171197 | 501c3 | $1,406,824 | Medical Research |
| Indiana University | |||||||
| Dept 78867 | Detroit | MI | 482780867 | 356001673 | 501c3 | $137,454 | Medical Research |
| Johns Hopkins University | |||||||
| Central Lockbox c/o B of A | Chicago | IL | 60693 | 520595110 | 501c3 | $468,431 | Medical Research |
| Jonathan Corren MD Inc | |||||||
| 10780 Santa Monica Blvd 280 | Los Angeles | CA | 90025 | 462346264 | 501c3 | $45,319 | Medical Research |
| Joslin Diabetes Center | |||||||
| ATTN Fiscal Services | Boston | MA | 022155306 | 042203836 | 501c3 | $62,425 | Medical Research |
| Massachusetts General Hospital | |||||||
| 55 Fruit Street | Boston | MA | 02114 | 042697983 | 501c3 | $5,841,834 | Medical Research |
| Medical University of South Carolina | |||||||
| 19 Hagood Avenue Ste 604 | Charleston | SC | 29425 | 576000722 | 501c3 | $15,919 | Medical Research |
| MITBroad Institute | |||||||
| 415 Main Street | Cambridge | MA | 02142 | 263428781 | 501c3 | $8,388 | Medical Research |
| National Jewish Health | |||||||
| 1400 Jackson Street M213 | Denver | CO | 80206 | 742044647 | 501c3 | $18,521 | Medical Research |
| New York University-School of Medicine | |||||||
| 1 Park Ave Fl 11 | New York | NY | 10016 | 135562308 | 501c3 | $19,272 | Medical Research |
| Northwestern University | |||||||
| 633 Clark Room G547 | Evanston | IL | 60208 | 362167817 | 501c3 | $91,798 | Medical Research |
| Ohio State University | |||||||
| Office of Sponsored Programs | Columbus | OH | 43210 | 316025986 | 501c3 | $12,616 | Medical Research |
| Polyclinic | |||||||
| Madison Center 904 7th Ave | Seattle | WA | 98104 | 910369070 | 501c3 | $39,093 | Medical Research |
| Rockefeller University | |||||||
| 1230 York Ave | New York | NY | 100656307 | 131624158 | 501c3 | $35,835 | Medical Research |
| Rutgers the State University of New Jersey | |||||||
| Office of Research and Sponsored Pr | New Brunswick | NJ | 089018559 | 226001086 | 501c3 | $126,221 | Medical Research |
| Sanford Research | |||||||
| 2301 E 60th St N | Sioux Falls | SD | 57104 | 460450378 | 501c3 | $81,778 | Medical Research |
| Seattle Childrens Hospital | |||||||
| PO Box 24728 | Seattle | WA | 981240728 | 910564748 | 501c3 | $528,866 | Medical Research |
| Stanford University | |||||||
| PO Box 44253 | San Francisco | CA | 941444253 | 941156365 | 501c3 | $283,911 | Medical Research |
| State University of Iowa | |||||||
| 118 S Clinton St - SCST | Iowa City | IA | 52242 | 426004813 | 501c3 | $71,518 | Medical Research |
| St Jude Children's Research Hospital Inc | |||||||
| PO Box 1000 Dept 949 | Memphis | TN | 381480949 | 620646012 | 501c3 | $290,310 | Medical Research |
| University Of South Florida | |||||||
| PO Box 864568 | Orlando | FL | 32886 | 593102112 | Florida | $7,679 | Medical Research |
| University of WA Grants | |||||||
| 12455 Collections Drive | Chicago | IL | 606930001 | 916001537 | Washington | $1,085,117 | Medical Research |
| Univ of Minnesota Regents | |||||||
| NW 5957 | Minneapolis | MN | 554855957 | 416007513 | Minnesota | $84,319 | Medical Research |
| University of Colorado-Denver | |||||||
| PO Box 910238 | Denver | CO | 802910238 | 846000555 | 501c3 | $185,610 | Medical Research |
| University of Pennsylvania | |||||||
| PO Box 785541 | Phliladelphia | PA | 171785541 | 231352685 | 501c3 | $172,206 | Medical Research |
| University of Florida | |||||||
| PO Box 113001 | Gainesville | FL | 32611 | 596002052 | 501c3 | $13,110 | Medical Research |
| University of Texas Southwestern Medical Center | |||||||
| 5323 Harry Hines Boulevard | Dallas | TX | 75390 | 756002868 | Texas | $103,452 | Medical Research |
| University of Michigan | |||||||
| Box 223131 | Pittsburgh | PA | 152512131 | 386006309 | 501c3 | $75,904 | Medical Research |
| University of North Carolina at Chapel Hill | |||||||
| PO Box 402420 | Atlanta | GA | 303842420 | 566001393 | 501c3 | $91,447 | Medical Research |
| University of Massachusetts Worcester | |||||||
| 55 Lake Avenue North | Worcester | MA | 016550002 | 043167352 | 501c3 | $11,810 | Medical Research |
| University of Wisconsin Madison Board of Regents | |||||||
| 600 Highland Ave | Madison | WI | 53792 | 396006492 | Wisconsin | $40,695 | Medical Research |
| University of Chicago | |||||||
| 5841 S Maryland Ave | Chicago | IL | 60637 | 362177139 | 501c3 | $11,025 | Medical Research |
| University of California San Francisco | |||||||
| Controllers Office | San Francisco | CA | 941430897 | 946036493 | 501c3 | $6,546,206 | Medical Research |
| University of Pittsburgh | |||||||
| Research/Cost Accounting | Pittsburgh | PA | 152517220 | 250965591 | 501c3 | $522,144 | Medical Research |
| University of Alabama at Birmingham | |||||||
| 1720 2nd Ave South | Birmingham | AL | 35294 | 636005396 | 501c3 | $9,860 | Medical Research |
| University of Miami | |||||||
| 1320 S Dixie Highway | Coral Gables | FL | 331462926 | 590624458 | 501c3 | $6,618 | Medical Research |
| University of California Los Angeles | |||||||
| 11000 Kinross Ave Ste 211 | Los Angeles | CA | 90095 | 956006143 | 501c3 | $36,807 | Medical Research |
| University Of Texas Health Science Center Houston | |||||||
| 7000 Fannin St | Houston | TX | 770305400 | 741761309 | Texas | $30,300 | Medical Research |
| Vanderbilt University | |||||||
| Department of Finance | Dallas | TX | 753121236 | 620476822 | 501c3 | $140,098 | Medical Research |
| Vital Prospects Clinical Research Institute PC | |||||||
| 7307 S Yale Ave Suite 200 | Tulsa | OK | 74136 | 261814411 | 501c3 | $13,903 | Medical Research |
| Washington University in St Louis | |||||||
| 700 Rosedale Avenue Campus Box 1034 | St Louis | MO | 63012 | 460653611 | Missouri | $10,601 | Medical Research |
| Weill Medical College of Cornell University | |||||||
| Attn Research Accounting | New York | NY | 100226102 | 131623978 | New York | $220,750 | Medical Research |
| Yale University | |||||||
| Grant and Contract Financial Admini | New Haven | CT | 065081873 | 080648973 | 501c3 | $28,249 | Medical Research |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 56 | Total501c3OrgCnt |
| Total Other Org | 1 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | Part I Line 2 | FormAndLineReferenceDesc |
| Explanation | Sub-recipient Monitoring Policy - medical research sub awards - BRI has formal policies and procedures to assure full compliance with applicable policies and laws governing federal grants. The Sub-recipient Monitoring Policy provides assurance that sub-recipients comply with federal grant regulations. This policy sets the criteria to establish eligibility of sub-recipients to provide annual audited financial reports and the annual OMB single audit report that identify compliance with federal laws and regulations. The reports are analyzed with emphasis on auditors assessment of sub-recipient internal controls and a standardized risk assessment is presented to management on each sub-recipient. A Management Letter is issued to each sub-recipient showing any findings on their OMB single audit report, and measurements are set for increased monitoring when an elevated level of risk is established. Management has communicated with an educated administrative staff regarding implementation of this policy. The Director of Grants and Contracts is responsible for monitoring sub-recipient adherence to financial regulations. The principal investigator is responsible for overseeing the satisfactory performance of the sub-award to ensure that goals are achieved. If there are unusual or unforeseen items, these will be investigated. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | Yes (X) | FirstClassOrCharterTravelInd |
| Club Dues Or Fees | Yes (X) | ClubDuesOrFeesInd |
| Written Policy Ref T And E Expnss | Yes (true) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (true) | SubstantiationRequiredInd |
| Severance Payment | false | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | false | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | false | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | false | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | false | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | false | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | false | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | false | AnyNonFixedPaymentsInd |
| Initial Contract Exception | false | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Michael Labosier | |||||||||||
| Chief Financial Officer | $191,450 | $19,000 | $6,562 | $217,012 | |||||||
| Lynn Rose | |||||||||||
| Director of Scientific Administration | $188,630 | $19,038 | $2,972 | $212,140 | $1,500 | ||||||
| Margaret McCormick PhD | |||||||||||
| Executive Director Chief Operating Officer | $218,634 | $25,000 | $5,800 | $249,434 | |||||||
| Steven Ziegler PhD | |||||||||||
| Director of Academic Affairs | $234,294 | $17,866 | $5,112 | $257,272 | |||||||
| William Kowk PhD | |||||||||||
| Research Member | $244,059 | $25,000 | $3,600 | $272,659 | |||||||
| Gerald Nepom MD PhD | |||||||||||
| Program Director, ITN | $158,330 | $24,000 | $3,444 | $185,774 | |||||||
| Gary Kaplan MD | |||||||||||
| Director | $1,204,109 | $193,393 | $264,290 | $287,869 | $43,155 | $1,992,816 | |||||
| David Aboulafia MD | |||||||||||
| Director | $634,300 | $1,188 | $27,343 | $31,801 | $694,632 | ||||||
| Joyce Lammert MD PhD | |||||||||||
| Director | $389,432 | $52,269 | $93,262 | $89,844 | $14,717 | $639,524 | |||||
| Carla Greenbaum MD | |||||||||||
| Director | $238,252 | $25,000 | $6,562 | $269,814 | |||||||
| Jane Buckner MD | |||||||||||
| Ex Officio, President | $391,383 | $25,000 | $1,200 | $518,618 | $101,035 | ||||||
| Homer Lane | |||||||||||
| Executive Director Chief Financial Officer | $88,163 | $6,125 | $860 | $175,536 | $80,388 | ||||||
| Daniel Campbell PhD | |||||||||||
| Center Director of Discovery Science | $186,514 | $12,425 | $5,304 | $204,243 | |||||||
| Bolong Cao | |||||||||||
| Business Development Director, Business Development | $186,128 | $25,000 | $4,474 | $215,602 | |||||||
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Line 1a | Social club dues are provided to two members of the senior leadership team who use the club memberships for business purposes. These payments are treated as non-taxable. |
| Part I Line 3 | Benaroya Research Institute at Virginia Mason BRI delegates to Virginia Mason Health Systems its parent and sole member Board Compensation and Benefits Committee, a committee composed of independent Health System Board members to whom the BRI Board has delegated the authority to approve all compensation and benefits for the executive leaders of BRI. To ensure that such benefit plans are market competitive and reasonable, the Committee receives support and advice, including appropriate market comparability data from an independent compensation consultant with expertise in the health care industry and access to relevant market data. See Schedule O for additional disclosure. |
| Part I Line 4b | The Virginia Mason Medical Center has a Supplemental Executive Retirement Plan SERP in which certain BRI Executives participate. The SERP is a 457 f nonqualified deferred compensation plan pursuant to which plan benefits are subject to a substantial risk of forfeiture, entered into in connection with certain senior executives joining the Medical Center. The plan was approved by the Boards Compensation and Benefits Committee, a committee composed of independent board members to whom the Board delegates the authority to approve compensation and benefits to the Medical Centers most senior executives. The Committee receives advice from an independent compensation consultant to ensure that compensation and benefits, including the SERP, are market competitive and reasonable. Supplemental Executive Retirement Plans such as this are customary for senior executives in the health care industry. |
Schedule K IRS990ScheduleK
Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp (2 entries)
| Bond ReferenceBondReferenceCd | Bond Issuer EINBondIssuerEIN | CUSIPCUSIPNum | Bond IssuedBondIssuedDt | Issue PriceIssuePriceAmt | PurposePurposeDesc | DefeasedDefeasedInd | On Behalf Of IssuerOnBehalfOfIssuerInd | Pool FinancingPoolFinancingInd |
|---|---|---|---|---|---|---|---|---|
| WA Econ Devel Fin Auth-2019 Series A | ||||||||
| A | 911493002 | 000000000 | 2019-02-26 | $25,716,490 | See Part VI | false | Yes (true) | false |
| WA Econ Devel Fin Auth-2019 Series B | ||||||||
| B | 911493002 | 000000000 | 2019-02-26 | $6,000,000 | See Part VI | false | Yes (true) | false |
Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp (2 entries)
| Bond ReferenceBondReferenceCd | RetiredRetiredAmt | Total ProceedsTotalProceedsAmt | Other Spent ProceedsOtherSpentProceedsAmt | Refunding Tax Exempt BondsRefundingTaxExemptBondsInd | Refunding Taxable BondsRefundingTaxableBondsInd | Final Allocation MadeFinalAllocationMadeInd | Adequate Books And Rec MaintAdequateBooksAndRecMaintInd | Capital ExpendituresCapitalExpendituresAmt |
|---|---|---|---|---|---|---|---|---|
| A | $569,384 | $25,716,490 | $25,716,490 | Yes (true) | false | Yes (true) | Yes (true) | |
| B | $6,000,000 | $5,736,573 | Yes (true) | false | Yes (true) | Yes (true) | $263,427 |
Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp (2 entries)
| Bond ReferenceBondReferenceCd | Owning Bond Financed PropertyOwningBondFinancedPropertyInd | Any Lease ArrangementsAnyLeaseArrangementsInd | Mgmt Contract Bond Fincd PropMgmtContractBondFincdPropInd | Any Research AgreementsAnyResearchAgreementsInd | Engage Bond Counsel ResearchEngageBondCounselResearchInd | Private Bus Use By OthersPrivateBusUseByOthersPct | Total Private Business UseTotalPrivateBusinessUsePct | Bond Iss Meet Prvt Sec Pymt TestBondIssMeetPrvtSecPymtTestInd | Change In Use Bond Financed PropChangeInUseBondFinancedPropInd | Procs Nonqualified Bond RemdtdProcsNonqualifiedBondRemdtdInd |
|---|---|---|---|---|---|---|---|---|---|---|
| A | false | false | false | Yes (true) | Yes (true) | 0.03030 | 0.03030 | false | false | Yes (true) |
| B | false | false | false | Yes (true) | Yes (true) | 0.03030 | 0.03030 | false | false | Yes (true) |
Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp (2 entries)
| Bond ReferenceBondReferenceCd | Form8038 T FiledForm8038TFiledInd | Rebate Not Due YetRebateNotDueYetInd | Variable Rate IssueVariableRateIssueInd | Hedge Identified In Bks And RecHedgeIdentifiedInBksAndRecInd | Gross Proceeds Invested In GICGrossProceedsInvestedInGICInd | Gross Proceeds InvestedGrossProceedsInvestedInd | Written Proc To Monitor ReqsWrittenProcToMonitorReqsInd |
|---|---|---|---|---|---|---|---|
| A | false | Yes (true) | Yes (true) | false | false | false | Yes (true) |
| B | false | Yes (true) | Yes (true) | false | false | false | Yes (true) |
Procedures Corrective Action ProceduresCorrectiveActionGrp (2 entries)
| Bond ReferenceBondReferenceCd | Procedures Corrective ActionProceduresCorrectiveActionInd |
|---|---|
| A | Yes (true) |
| B | Yes (true) |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Part I Line A Column F | Purposes To currently refund WEDFA Series 2012 B bonds issued 06/01/2012, and WEDFA Series 2016 bonds issued on 06/01/2016. |
| Part I Line B Column F | Purposes To fund research facility improvements and equipment purchases on a draw-down basis over a three-year period ending in 2022. |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (14 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| Form 990, Part III, Line 1 | Benaroya Research Institute at Virginia Mason BRI is one of the few research institutes in the world devoted to finding causes and cures for autoimmune disease and other diseases of the immune system including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, lupus, inflammatory bowel disease, allergy and cancer. We believe a breakthrough against one of these diseases can lead to progress against them all. BRI is affiliated with the Virginia Mason Health System, which provides governance oversight, development support through the Virginia Mason Foundation as well as being a partner in clinical and translational research. In 2019, BRI launched an ambitious strategic plan with a bold mission to predict, prevent, reverse and cure diseases of the immune system to achieve our vision of a healthy immune system for everyone. Discoveries at BRI are accelerated by our talented researchers, collaborative culture and application of new technologies and data analytics. However, in order to fully realize our mission, we need to better understand what causes the immune system to fall out of balance and what we can do to restore it to health. To that end, BRI has now organized its scientific activities into four new Centers of Discovery 1 Fundamental Immunology, directed by Daniel Campbell, PhD 2 Translational Immunology, directed by Karen Cerosaletti, PhD 3 Interventional Immunology, directed by Carla Greenbaum, MD and 4 Systems Immunology, directed by Peter Linsley, PhD. The Centers work together by building on the discoveries of each, with scientists applying tools and insights across the spectrum of immune system diseases to accelerate research advances. BRI is led by President Jane H. Buckner, MD, and Executive Director/COO Margaret McCormick, PhD. In 2019, through a new funding opportunity BRI initiated a novel Gut Immunology program, which works across the Centers to unite scientists who study different aspects of the same diseases. Many of BRIs research faculty serve concurrently as affiliate professors at the University of Washington and mentor postdoctoral fellows, graduate students and summer interns. |
| Form 990, Part III, Line 4 | One unique quality of BRI is the close integration of four types of medical research - laboratory research, translational research, clinical research and systems biology - to improve lives. Our scientists collaborate to explore basic science as well as clinical applications, which is the best way to design studies with the highest potential for success. At BRI, discovery starts in the laboratory but is driven by patient issues addressed in the clinic. Selected 2019 advancements of the Immune Tolerance Network and in BRIs Centers of Discovery are highlighted as follows. |
| Form 990, Part III, Line 4a | Funding for the Immune Tolerance Network ITN was awarded to BRIs Dr. Jerry Nepom in 2014 from the National Institute of Allergy and Infectious Disease NIAID of the National Institutes of Health NIH. The 7-year award, totaling 27 million annually supports the ITN, a research consortium established in 1999 with a primary focus on the development of new tolerogenic approaches for the treatment and prevention of disease in these clinical areas Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. As the Prime recipient of this grant, BRI is responsible for the management of the overall grant from NIAID including oversight of all aspects of the Networks infrastructure. The major activities in 2019 were diverse, but continued to center on preserving the ITNs cohesive project focused environment and its framework which has proven so successful in the management of a large cooperative agreement grant. Key outcomes in 2019 include the following 1 Cross Network Integration A top priority in this reporting period was to continue the successful ITN infrastructure which is spread across three main operational sites. This required careful planning and collaboration as the ITNs major centers of operations are geographically diverse, located in Seattle, San Francisco and Bethesda. Few changes were made to the existing network integration as the current model continues to successfully support the overall ITN program. Establishing new relationships and vital connections within the research community continued to be an ITN goal. 2 Operations and Clinical Trial Support The ITN program team at BRI issued 194 sub-awards in 2019 in support of 27 active ITN clinical trials and numerous supporting ITN mechanistic trials. 3 Supplemental Funding / Partnerships ITN central administration continued to focus on identifying additional opportunities for supplemental funding and/or funding partnerships. a Supplemental Funding Opportunities The ITN Program Team at BRI submitted two supplemental funding requests in 2019. These requests were awarded, bringing in an additional 3.17M in funding to the ITN BRI. b Partnerships The ITN continued its relationship with two pharmaceutical partners for partial funding on two ongoing ITN studies. NIAID is the clinical sponsor on both of these trials. 4 Publication Activity In 2019, 26 ITN publications were published in prestigious research journals and were presented at domestic and international research conferences. These publications represented ITN research in all therapeutic focus areas of the ITN Type 1 Diabetes, Transplant, Autoimmune disease and Allergy and Asthma. 5 Grant Renewal Application With the current ITN grant funding ending in February 2021, the preparation of the grant renewal application was a major focus in Q4, 2019. The renewal was successfully submitted, with expected award notification in late 2020. |
| Form 990, Part III, Line 4b | Center of Fundamental Immunology advances include 1 Linking a New Type of Cell with a Deadly Inflammatory Disorder - A research team made a discovery that lights the way to treat life-threatening complications of autoimmune and viral diseases. The discovery, published in the journal Science, could lead to new treatments for a deadly form of inflammation in children with systemic juvenile idiopathic arthritis SJIA, malaria and Kawasaki disease as well as patients with lupus. The research team found a unique type of cell, which they termed inflammatory hemophagocytes iHPCs, that eat red blood cells in MAS and malaria. They demonstrated that iHPCs develop under the influence of two specific proteins that recognize infection and are associated with autoimmune disease. Next steps will involve collaborations with pediatricians and pediatric rheumatologists to look for iHPCs in the blood of children with autoimmune disease related anemia, as well as healthy individuals, with a goal of quickly identifying potential targets for treatments. Comparisons with blood samples infected by malaria are already under way. 2 A Skin Immune Cell Discovery Challenges Assumptions about T cells - BRI scientists scrutinized a newly identified population of human immune cells in the blood that appear to have everything in common with infection-fighting T cells isolated from the skin. Scientists demonstrated that T cells that were previously assumed to stay in the skin, and are referred to as tissue-resident memory T cells, can exit skin tissue, enter the blood and circulate throughout the body. These T cells can then relocate into skin at other locations of the body. In addition to potential implications for treatment of wounds and skin infections, the identification of this cell population presents an opportunity to identify therapies for immune-related diseases that affect the skin, including scleroderma, psoriasis and a form of lymphoma called mycosis fungoides. |
| Form 990, Part III, Line 4c | Center for Translational Immunology is a research approach that allows scientific observations made in the basic research lab to be quickly evaluated in patient samples, refining our understanding of human disease in an expedient and systematic way. This research is translating new diagnostic and treatment approaches that may improve our ability to predict disease risk, prevent onset of disease, decrease disease progression and make treatments safer and better. The research emphasis of the BRI Translational Research Program crosses a spectrum of diseases caused by or aggravated by the immune system, including cancer and infectious disease. The BRI biorepositories, or biobank, is a collection of blood, serum and tissue samples, as well as medical histories, from healthy volunteers and individuals with diseases involving the immune system. Sample collections began in 2000. BRI scientists and physician collaborators work together to study the blood and serum samples along with medical and demographic data collected from people with autoimmune and immune-mediated diseases. These include multiple sclerosis, type 1 diabetes, lupus, rheumatoid arthritis, inflammatory bowel disease, allergy, asthma and cancer. Advancements in 2019 included the following 1 Personalized Treatments for Peanut Allergy - BRI furthered a two-pronged study to accelerate discovery of treatments for peanut allergy through a collaboration involving three BRI labs, Virginia Mason physicians and sponsors of two clinical trials. The study first investigated peanut allergy patients immune responses and classified them into subgroups. In the second part of the study, researchers are evaluating treatment options used in a pair of clinical trials to determine how specific treatments can be matched to specific patients to teach their immune systems to tolerate peanut protein. 2 Sound Life Project - BRI launched the Sound Life Project, a two-year study in which researchers will track healthy immune systems over time. Seattle-area adults in two age cohorts - 25-35 and 55-65 - began to participate in this groundbreaking study to build a baseline of knowledge about the human immune system and the influence of environmental/lifestyle factors. BRI will use this information about healthy immune systems to serve as a foundation for existing and future disease research programs. The project is in the initial phase of a research partnership led by the Allen Institute for Immunology. 3 Autoimmune Disease Research in the Down Syndrome Population - With the help of a Virginia Mason pediatrician, BRI leveraged a grant from the National Institutes of Health to build a Down syndrome DS biorepository to research the connection between DS and autoimmune disease. The collection includes blood, serum and tissue samples, as well as medical histories, from volunteers, people with DS and their relatives, with and without autoimmune diseases. The DS population has long been underrepresented in medical research, and nearly 50 percent of this population is living with at least one autoimmune disease. BRI is among the first to be awarded a grant dedicated to autoimmune disease in the DS population. 4Identifying biomarkers that predict the success of checkpoint inhibitor immunotherapy drugs used to treat certain types of cancer - Despite the success of checkpoint inhibitors at improving cancer survival rates, they do not work in all patients and often have serious side effects including sudden-autoimmune-like symptoms called immune related adverse events irAEs. BRI scientists took a much closer look at how immune response cells -- known as T cells -- are affected by checkpoint inhibitor drugs. Ultimately, the scientists hope to identify T cell biomarkers that predict which patients are at the lowest or highest risk for autoimmune effects after receiving checkpoint inhibitors. They also explored ways to improve the ability of checkpoint inhibitors to kill cancer cells while protecting healthy tissue. The BRI Clinical Research Program works closely with oncologists at Virginia Mason to enroll subjects in this study. In a second project involving immunotherapy, BRI scientists collaborated to understand, predict and prevent insulin-dependent diabetes following checkpoint therapy for cancer. After treatment with checkpoint inhibitors, roughly 1 of cancer patients develop a kind of insulin-dependent diabetes that appears similar to type 1 diabetes. The goal of this collaborative research initiative was to better understand this phenomenon and to identify the causes of diabetes in these patients. The autoimmunity research collaborators also intended to shed light on the causes of T1D in the broader population. |
| Form 990, Part III, Line 4c continued | 5 Pursuing a Revolution in IBD Treatment - BRI researchers searched for biomarkers that could help make IBD treatment more precise and effective through a precision medicine approach that could tailor treatment to individual patients. They worked to identify biomarkers - proteins and other molecules in patients blood or cells - to predict response to a specific drug. The researchers started this study by taking blood samples from Virginia Mason IBD patients before they started using the drug vedolizumab, and then again after they had taken several doses, carefully analyzing the immune cells in these samples. Vedolizumab binds to a specific type of receptor on the outside of some immune cells, and the researchers discovered that some people who have more of this receptor respond better to the drug. 6 Aiming for Better Lupus Treatments - Immune cells protect us by hunting down bacteria and viruses, but a BRI team found that cells that lack a gene called ATG5 never stop attacking. Eventually, they aim at healthy cells and cause lupus. Scientists think it might be possible to stop these attacks by using medications to reactivate ATG5 and other genes, which could switch off overactive immune cells. A second research team identified a different gene involved in lupus BANK1. This gene plays a role in immune cells called B cells. Many B cells make tiny proteins called antibodies, and some of those antibodies attack healthy cells, causing lupus. The team showed that BANK1 may increase the number of B cells that make antibodies, especially in people with lupus who have a particular BANK1 variant. The work is helping us move toward better, more personalized treatments of lupus. |
| Form 990, Part III, Line 4c continued | The Center for Interventional Immunology translates discoveries in the lab to patient therapies in the clinic through small and large-scale clinical studies. The Center for Interventional Immunology is also home to the Diabetes Clinical Research Program as well as the Clinical Research Program CRP, which provides compliance oversight of all interventional studies at BRI and Virginia Mason Medical Center. The CRP also manages all clinical research conducted by Virginia Mason Medical Center physicians and supports a number of specimen collection protocols developed within the Translational Immunology Center, particularly in cancer research. Details about CRP activities are provided below. Advancements in 2019 included the following 1 BRI leads the Type 1 Diabetes TrialNet, a National Institutes of Health-funded clinical trial network for type 1 diabetes prevention and early treatment, serving as the TrialNet hub of 28 clinical centers working with more than 200 screening and clinical research sites across the U.S. and six other countries. 2 An Immunotherapy Drug that can Delay T1D - A TrialNet prevention study involving diabetes researchers and volunteers at BRI showed a drug that targets the immune system - teplizumab - can delay type 1 diabetes a median of two years in children and adults at high risk. That is good news for relatives of people with type 1 diabetes, who are at 15 times greater risk of the disease than the general population. Samples collected during the trial are being studied to help researchers understand why certain people responded to the drug better than others, and next, researchers hope to conduct additional studies to look for ways to extend the benefits of the drug. 3 The TrialNet Pathway to Prevention study screened relatives of people with type 1 diabetes to find out if these family members are at risk for developing diabetes. Relatives of people with type 1 diabetes have about a three to four percent chance of testing positive for autoantibodies associated with diabetes. At-risk relatives are offered additional tests to estimate their chances of developing type 1 diabetes. Those who qualify have the opportunity to enroll in a prevention trial. All research volunteers are closely monitored for early detection of type 1 diabetes. Early detection of type 1 diabetes may improve blood sugar control and reduce the chances of complications. 4 Home to the JDRF Core for Clinical Assay Validation CAV, BRI plays an important role in identifying type 1 diabetes biomarkers and in helping outside researchers get the most accurate test results. The CAV is pinpointing key biomarkers, such as those indicating which patients will keep making insulin for years and which patients wont. The CAV also helps maintain quality control for a worldwide network of research labs by asking them to perform specific tests and reviewing their results. 5 The Center for systems Immunology analyzes large and complex data sets across all the other Centers, to identify patterns that accelerate discovery and disease breakthroughs. Advancements in 2019 included the following Identifying and helping T1D fast progressors - When some people are diagnosed with type 1 diabetes T1D, the disease progresses so quickly that their pancreas stops making insulin within a year. For others, the process is slower and their disease is easier to manage. BRI researchers revealed that it is possible to identify the fast progressors early and match them with treatments that help keep them healthy for longer. This research showed that slow progressors have higher levels of exhausted CD8 T cells - cells that are worn out from attacking the pancreas. The discovery could lead to a test that identifies how quickly individual patients will lose their ability to make insulin. |
| Form 990, Part III, Line 4d | Clinical Research Program Benaroya Research Institute oversees all clinical research at Virginia Mason Medical Center, which combines the expertise of BRI in management of interventional studies with the remarkable care of a quality healthcare leader. The BRI Clinical Research Program supports BRI and Virginia Mason clinical investigators in studies across a wide variety of autoimmune and immune-mediated diseases and conditions, as well as a broad range of other diseases such as cancer and cardiac disease. Each year the Clinical Research Program staff enrolls approximately 1500 study participants into Virginia Mason trials. This program involves approximately 150 research investigators at Virginia Mason Medical Center, and oversees more than 400 active studies with more than 275 studies currently open to enrollment. Teaming Up Against Celiac Disease - Researchers used tetramer technology pioneered by a BRI scientist and used to isolate particular immune cells to pinpoint attacker T cells in blood samples from patients with celiac disease. In these patients, only about three in 100,000 T cells react to gluten, sparking immune attacks that lead to the diseases debilitating symptoms. The researchers are working to figure out why these cells attack the body, perhaps leading them to diagnostic tools and therapies for patients with celiac symptoms - as well as their family members, because autoimmune disease can run in families. Testing a New MS Therapy - a research study at BRI and Virginia Mason seeks to find out if an experimental oral drug, similar to a currently available MS medication, would be just as effective as the current one, but with fewer gastrointestinal side effects. In an earlier study, half the research participants took this experimental drug and half took the current drug. Participants who finished the five-week study then enrolled in a two-year study of the experimental drug, under way in 2019. |
| Form 990, Part VI, Section A, Line 1a | The governing body delegates to an Executive Committee comprised of four officers of the Board and the Chairs of each standing Board Committee, the authority of the Board of Directors in the management of the corporation as may be deemed by the Executive Committee to be appropriate, to be exercised in time periods between regularly scheduled meetings of the Board of Directors provided that the Executive Committee has the authority to act only in time sensitive or emergency situations. The President and the Executive Director of the corporation serve as ex officio members of the Executive Committee without voting rights. The Executive Committee does not have the authority to amend, alter or repeal the bylaws elect, appoint or remove any member of such Executive Committee or any director or officer of the corporation amend the articles of incorporation adopt a plan of merger or adopt a plan of consolidation with another corporation authorize the sale, lease or exchange of all or substantially all of the property and assets of the corporation not in the ordinary course of business authorize the voluntary dissolution of the corporation or revoke proceedings therefore adopt a plan for the distribution of the assets of the corporation or amend, alter or repeal any resolution of the Board which by its terms provides that it shall not be amended, altered or repealed by such Executive Committee. The Executive Committee also serves as the planning committee for the Board of Directors and oversees any compliance issues raised by the Board of Directors. |
| Form 990, Part VI, Section A, Line 6,7 | Virginia Mason Health System VMHS is the sole corporate member of Benaroya Research Institute at Virginia Mason BRI. VMHS as the sole voting member has the following approval rights a election or appointment of Directors and Officers of the Board of Directors b removal of Directors and Officers of the Board of Directors including any executive officer of the corporation c approval of all long-range and short-range plans proposed by the Board of Directors d approval of the annual capital and operating budgets proposed by the Board of Directors e approval of the borrowing of funds where the amount borrowed is in excess of Five Hundred Thousand Dollars 500,000 f approval of the sale, lease, exchange, mortgage, pledge or disposal of all or substantially all of the property and assets g approval of all amendments to or repeal of the Agreement Association or the Bylaws of the corporation h all other rights and powers as specified in the Washington Nonprofit Corporation Act. |
| Form 990, Part VI, Section B, Line 11b | The VMHS Audit and Compliance Committee ACC, a committee composed of independent community members has been delegated responsibility for oversight of the annual Form 990 preparation process including a selection, engagement, and review of the performance of the independent tax preparer b review of the annual draft Form 990 tax return, and c recommendation of the final Form 990 tax return for review to the BRI Board of Directors. Annually, at the September meeting, management and the tax preparer provide the ACC with an initial draft of the Form 990 and present an overview of the Form 990 preparation process. The final Form 990 is reviewed by the ACC in November followed by a Board review of the final Form 990 prior to filing. The final Form 990 tax return is provided to each member of the Board of Directors via electronic delivery. |
| Form 990, Part VI, Section B, Line 12c | The VMHS Governance Committee has been delegated accountability for oversight of the process for disclosure, evaluation and management of conflict of interest involving any member of the BRI Board of Directors, executive leadership or key employees Covered Person. Pursuant to the Conflict of Interest Policy, an annual conflict of interest questionnaire is distributed to all Covered Persons. In addition, a Covered Person has an on-going duty to disclose the existence of a conflict of interest at any time an actual or potential conflict arises. Each Covered Person is required upon appointment and annually thereafter to attest to a statement that affirms that such person has a received a copy of the Conflict of Interest Policy b has read and understands the Policy c has agreed to comply with the Policy and d understands that BRI is a charitable organization and that in order to maintain its federal tax exemption must engage in activities that accomplish its tax-exempt purposes. Written disclosures are reviewed by the Governance Committee to determine if an actual or potential conflict of interest exists and if so, how it should be managed. The Covered Person is informed in writing regarding the determination the Conflict of Interest Management Plan. No Covered Person with an actual or potential conflict of interest shall engage in an activity on BRIs behalf related to the disclosed actual or potential Conflict of Interest unless such activity is permitted by the Conflict of Interest Management Plan or until the Covered Person has undertaken all steps set forth in the Management Plan to manage, reduce or eliminate the conflict. All Covered Persons have a duty to disclose the existence of any actual or potential conflict of interest with respect to meeting agenda items. The Conflict of Interest Policy requires that copies of the Conflict of Interest Questionnaire be completed annually by each covered Person and any Conflict of Interest Management Plan be maintained. |
| Form 990, Part VI, Section B, Line 15 | The VMHS Compensation and Benefits Board Committee, a committee composed solely of independent directors none of whom have a conflict of interest, is accountable for setting reasonable total compensation packages for each executive, officer and key employee Executive consistent with BRIs compensation philosophy and principles. The Committee approves annual goals and performance criteria which are used in determining merit increases and variable compensation opportunities. The Committee assesses performance against these goals. The Committee selects and engages a qualified independent compensation consultant to review and analyze the total compensation and benefits packages of the Executives. The Committee as part of its analysis obtains from the compensation consultant appropriate comparability data including total compensation paid by similarly situated organizations for positions that are functionally comparable to each of the Executives. The Committee will consider the significant terms of the agreement with each Executive including the total compensation to be paid and the employees duties and responsibilities. Consistent with the compensation philosophy and principles, the Committee approves total compensation packages for each of the Executives based on information presented to the Committee, reasonableness and the best interest of BRI. The Committees decisions regarding compensation for each Executive are documented in written resolutions and minutes of the Committee. The Committee promptly reports its actions to the VMHS board which reports are reflected in the Boards minutes. The individual positions who were reviewed in 2019 were Jane Buckner, BRI President and Director, Carla Greenbaum, BRI Director, Margaret McCormick, Executive Director and Chief Operating Officer, and Michael Labosier, Chief Financial Officer. |
| Form 990, Part VI, Section C, Line 19 | The organizations Articles, Bylaws, Conflict of Interest Policy and financial statements are made available upon request. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (4 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Direct Controlling NADirectControllingNACd | Controlled OrganizationControlledOrganizationInd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Virginia Mason Health System | |||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 911351110 | Fundraising | WA | Sec 501c3 | 7 | N/A | false | |
| Virginia Mason Medical Center | |||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 910565539 | Health Care | WA | Sec 501c3 | 3 | false | VMHS | |
| Virginia Mason Institute | |||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 263763656 | Education | WA | Sec 501c3 | 9 | false | VMMC | |
| Yakima Valley Memorial Hospital Association | |||||||||||
| 2811 Tieton Drive | Yakima | WA | 98902 | 910567263 | Health Care | WA | Sec 501c3 | 3 | false | VMHS | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | false | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | false | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (true) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | false | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | false | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | false | DivRelatedOrganizationInd |
| Asset Sale To Other Org | false | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | false | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | false | AssetExchangeInd |
| Rental Of Facilities To Oth Org | Yes (true) | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | Yes (true) | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | false | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | false | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (true) | SharingOfFacilitiesInd |
| Paid Employees Sharing | false | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | Yes (true) | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | Yes (true) | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | false | TransferToOtherOrgInd |
| Transfer From Other Org | false | TransferFromOtherOrgInd |
Affiliated Group Schedule AffiliatedGroupSchedule
Affiliated Schedule AffiliatedScheduleGrp (5 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Total Grassroots LobbyTotalGrassrootsLobbyAmt | Total Direct LobbyTotalDirectLobbyAmt | Total Lobby ExpenditureTotalLobbyExpenditureAmt | Other Exempt Purpose ExpendOtherExemptPurposeExpendAmt | Total Exempt Purpose ExpendTotalExemptPurposeExpendAmt | Lobby NontxLobbyNontxAmt | Grassroots NontxGrassrootsNontxAmt | Total Lobby Grssroot Mns NontxTotalLobbyGrssrootMnsNontxAmt | Tot Lbby Expend Mns Lobby NontxTotLbbyExpendMnsLobbyNontxAmt | Share Excess Lobby ExpendShareExcessLobbyExpendAmt | Electing OrganizationElectingOrganizationInd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benaroya Research Institute at Virginia Mason | |||||||||||||||
| 1200 Ninth Avenue | Seattle | WA | 98101 | 910653422 | $0 | $0 | $0 | $71,446,676 | $71,446,676 | $40,449 | $10,112 | $0 | $0 | $0 | |
| Virginia Mason Medical Center | |||||||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 910565539 | $134,909 | $63,581 | $198,490 | $1,174,521,397 | $1,174,719,887 | $665,053 | $166,263 | $0 | $0 | $0 | Yes (X) |
| Virginia Mason Institute | |||||||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 263763656 | $0 | $0 | $0 | $6,260,831 | $6,260,831 | $3,544 | $886 | $0 | $0 | $0 | |
| Virginia Mason Health System | |||||||||||||||
| 1100 Ninth Avenue | Seattle | WA | 98101 | 911351110 | $0 | $0 | $0 | $14,136,817 | $14,136,817 | $8,003 | $2,001 | $0 | $0 | $0 | |
| Yakima Valley Memorial Hospital Association | |||||||||||||||
| 2811 Tieton Drive | Yakima | WA | 98902 | 910567263 | $48,610 | $60,000 | $108,610 | $499,682,326 | $499,790,936 | $282,950 | $70,738 | $0 | $0 | $0 | |